COMMUNIQUÉS West-GlobeNewswire

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe

27/06/2017 - 08:00

Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical- [...]

Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union

27/06/2017 - 07:00

Sanofi and Regeneron Announce Approval of Kevzara ® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union Paris, France and Tarrytown, N.Y., June 27, 2017 - [...]

Sanofi et Regeneron annoncent l'approbation de Kevzara® (sarilumab) dans l'Union européenne pour le traitement de la polyarthrite rhumatoïde active, modérée à sévère, de l'adulte

27/06/2017 - 07:00

Sanofi et Regeneron annoncent l'approbation de Kevzara ® (sarilumab) dans l'Union européenne pour le traitement de la polyarthrite rhumatoïde active, modérée à sévère, de l'adulte Paris (France) et Tarrytown (New York [...]

ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC., KENILWORTH, NEW JERSEY, USA

27/06/2017 - 07:00

GHENT, Belgium, 27 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Merck & Co., Inc., Kenilworth, New Jersey, USA, known as MSD outside the United States and Canada, has started an IND- [...]

Ossur Hf : Transactions in relation to share buyback program

26/06/2017 - 18:00

Announcement from Össur hf. No. 46/2017 Reykjavík, 26 June 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]

Sanofi : Disclosure of trading in own shares

26/06/2017 - 18:00

Reporting EN This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Sanofi : Déclaration des transactions sur actions propres

26/06/2017 - 18:00

Reporting FR This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Scientific breakthrough on objective diagnosis of PTSD

26/06/2017 - 16:51

Scientific breakthrough for non-invasive, automatic, objective diagnosis of PTSD leveraging autonomic biomarkers Accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD Medibio has exclusive worldwide [...]

Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients

26/06/2017 - 15:00

DUBLIN - June 26, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a new outcomes-based agreement with Aetna (NYSE:AET) for type 1 and type 2 diabetes patients currently on [...]

Novo Nordisk A/S - Share repurchase programme

26/06/2017 - 13:40

Bagsværd, Denmark, 26 June 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]

Targovax ASA: Registration of capital increase following exercise of employee options and settlement of restricted stock units

26/06/2017 - 09:40

Reference is made to the stock exchange notice of 14 June 2017 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the exercise of employee [...]

Mithra Pharmaceuticals: ESTELLE® PHASE IIB RESULTS ON WELL-BEING AND BODY WEIGHT PUBLISHED IN LEADING PEER-REVIEWED JOURNAL

26/06/2017 - 07:30

PRESS RELEASE Estelle® Phase IIb results on well-being and BODY weight published in LEADING peer-reviewed journal European Journal Of Contraception and Reproductive Health Care publishes article on Phase IIb results of [...]

ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS

26/06/2017 - 07:00

To assess the safety and tolerability of single and multiple doses of caplacizumab in Japanese healthy volunteers To compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of caplacizumab in Japanese and [...]

INNATE PHARMA : Results of Annual General Meeting and changes to Innate Pharma's governance and management team

26/06/2017 - 07:00

Results of Annual General Meeting and changes to Innate Pharma's governance and management team · All proposed resolutions were voted according to management's recommendations; · Bpifrance Participations, represented by [...]

INNATE PHARMA : Résultats de l'Assemblée générale et évolutions au sein de la gouvernance et du management de la société

26/06/2017 - 07:00

Résultats de l'Assemblée générale et évolutions au sein de la gouvernance et du management de la société Toutes les résolutions proposées ont fait l'objet d'un vote conforme aux recommandations du Directoire ; Bpifrance [...]

Bone Therapeutics SA: Receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform

26/06/2017 - 07:00

Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform European IP protection for company's allogeneic technology expected until 2029 Gosselies, Belgium, [...]

Bone Therapeutics SA: Reçoit de l'Office Européen des Brevets une notification d'intention de délivrer un brevet pour sa plateforme de thérapie cellulaire osseuse allogénique

26/06/2017 - 07:00

Bone Therapeutics reçoit de l'Office Européen des Brevets une notification d'intention de délivrer un brevet pour sa plateforme de thérapie cellulaire osseuse allogénique Protection de la Propriété Intellectuelle liée à [...]

NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

23/06/2017 - 18:00

Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved event-free survival in [...]

Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017

23/06/2017 - 17:34

Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017 - Dr. Nils Clausnitzer elected as member of the Supervisory Board Amsterdam, the Netherlands, and Holzgerlingen, Germany, June 23, 2017 -- [...]